Primary Site >> Colorectal Cancer
Gene >> CD274
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. PMID: 15611321 |
Ref: Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. PMID: 17591743 |
Ref: Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. PMID: 20924130 |
Ref: Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. PMID: 21788356 |
Ref: B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. PMID: 22408358 Ref: Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice. PMID: 22610745 Ref: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. PMID: 22658127 Ref: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. PMID: 22658128 Ref: The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. PMID: 22719018 Ref: Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. PMID: 23087408 Ref: [Expression of Bcl-2, PD-L1 and its clinical significance in colorectal cancer]. PMID: 23387206 |
Ref: Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PMID: 23437326 Ref: Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. PMID: 23478000 Ref: Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. PMID: 23633484 Ref: PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PMID: 23785454 Ref: B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PMID: 24124529 |
Ref: T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China's Heilongjiang province. PMID: 23873101 Ref: MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. PMID: 24468585 Ref: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. PMID: 24714771 Ref: B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. PMID: 25053455 Ref: PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. PMID: 25093496 Ref: Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. PMID: 25287912 Ref: Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. PMID: 25392179 |
Ref: The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. PMID: 25358689 Ref: The potential role of immunotherapy to treat colorectal cancer. PMID: 25519074 Ref: The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. PMID: 25583798 Ref: Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. PMID: 25730880 Ref: Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. PMID: 25919090 Ref: Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. PMID: 25943534 Ref: An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. PMID: 25949894 Ref: PD-L1 blockade for cancer treatment: MEDI4736. PMID: 25965366 Ref: PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PMID: 26114883 Ref: Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? PMID: 26140250 Ref: Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. PMID: 26187615 Ref: Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. PMID: 26209749 Ref: B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells. PMID: 26284927 Ref: Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. PMID: 26317899 Ref: Correlation study of Bcl-2, B7-H1, EGFR, VEGF and colorectal cancer. PMID: 26328258 Ref: Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. PMID: 26452385 |
Ref: PD-L1 expression in tumour buds of colorectal carcinoma. PMID: 26648188 Ref: moCluster: Identifying Joint Patterns Across Multiple Omics Data Sets. PMID: 26653205 Ref: Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. PMID: 26683225 Ref: Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. PMID: 26891728 Ref: IL-15 superagonist/IL-15RalphaSushi-Fc fusion complex (IL-15SA/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. PMID: 26910920 Ref: Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. PMID: 26919982 Ref: PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. PMID: 26933175 Ref: Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. PMID: 26959743 Ref: Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. PMID: 26965581 Ref: Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. PMID: 26982367 Ref: Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer. PMID: 27006653 Ref: Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. PMID: 27039171 Ref: Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. PMID: 27070448 Ref: Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. PMID: 27080226 Ref: Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. PMID: 27106868 Ref: Dendritic cell-based cancer immunotherapy for colorectal cancer. PMID: 27158196 Ref: Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. PMID: 27197062 Ref: PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. PMID: 27198569 Ref: Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells. PMID: 27221508 Ref: Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? PMID: 27229745 Ref: The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. PMID: 27248318 Ref: Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. PMID: 27339628 Ref: [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "a la carte" treatment?]. PMID: 27345450 Ref: Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. PMID: 27363678 Ref: Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. PMID: 27443512 Ref: Antitumor Effect of Zhihuang Fuzheng Soft Capsules on Tumor-Bearing Mice. PMID: 27493673 Ref: Visceral fat adipocytes from obese and colorectal cancer subjects exhibit distinct secretory and omega6 polyunsaturated fatty acid profiles and deliver immunosuppressive signals to innate immunity cells. PMID: 27494857 Ref: Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen. PMID: 27496709 Ref: Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. PMID: 27530650 Ref: Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. PMID: 27552968 Ref: The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. PMID: 27553906 Ref: PD-L1 expression in human cancers and its association with clinical outcomes. PMID: 27574444 Ref: Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition. PMID: 27622019 Ref: Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. PMID: 27651308 Ref: 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. PMID: 27777774 Ref: The evolving role of microsatellite instability in colorectal cancer: A review. PMID: 27838401 Ref: Programmed death-ligand 1 expression in rectal cancer. PMID: 28058043 Ref: The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. PMID: 28123883 Ref: CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. PMID: 28123896 Ref: A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. PMID: 29263903 Ref: PD-L1 in melanoma: facts and myths. PMID: 30190888 |
Ref: Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. PMID: 27196573 Ref: Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. PMID: 27470134 Ref: Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. PMID: 27813511 Ref: Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. PMID: 28055269 Ref: Increased PD-L1 expression in breast and colon cancer stem cells. PMID: 28107571 Ref: PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. PMID: 28197377 Ref: Immunoprofiling as a predictor of patient's response to cancer therapy-promises and challenges. PMID: 28222333 Ref: Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells. PMID: 28223102 Ref: Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. PMID: 28267224 Ref: Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. PMID: 28287848 Ref: Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy. PMID: 28373465 Ref: The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the 'immunoreactive' microenvironment of colorectal carcinoma. PMID: 28383777 Ref: Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. PMID: 28405764 Ref: Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. PMID: 28406723 Ref: The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5. PMID: 28423711 Ref: Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. PMID: 28459943 Ref: PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. PMID: 28514441 Ref: Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth. PMID: 28589725 Ref: Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. PMID: 28595259 Ref: Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. PMID: 28597080 Ref: [Bone Morphogenetic Proteins from CT26 Regulate the Expression of PD-L1 in Murine Dendritic Cells and Macrophages]. PMID: 28612555 Ref: Immune Checkpoints as a Target for Colorectal Cancer Treatment. PMID: 28635639 Ref: MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer. PMID: 28693258 Ref: Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. PMID: 28721097 Ref: Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy. PMID: 28726535 Ref: PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. PMID: 28811964 Ref: Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy. PMID: 28851046 Ref: Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review. PMID: 28915720 Ref: PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer. PMID: 28932634 Ref: PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. PMID: 28938609 Ref: PD-L1 expression in HNPCC-associated colorectal cancer. PMID: 29033182 Ref: Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. PMID: 29038297 Ref: Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression. PMID: 29085667 Ref: Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. PMID: 29093678 Ref: The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3. PMID: 29102042 Ref: Prediction of radio-responsiveness with immune-profiling in patients with rectal cancer. PMID: 29108360 Ref: The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. PMID: 29113654 Ref: Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment. PMID: 29156738 Ref: [Immunotherapy of Colorectal and Anal Carcinoma]. PMID: 29239195 Ref: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PMID: 29284010 Ref: Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology. PMID: 29552640 |
Ref: PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker. PMID: 27801734 Ref: Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives. PMID: 28183254 Ref: PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. PMID: 28667193 Ref: The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. PMID: 28922790 Ref: Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-betaGal and MVA-MUC1 (TG4010) in a murine tumor model. PMID: 28925793 Ref: A novel histological examination with dynamic three-dimensional reconstruction from multiple immunohistochemically stained sections of a PD-L1-positive colon cancer. PMID: 28940664 Ref: Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. PMID: 29044503 Ref: Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo. PMID: 29115601 Ref: Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. PMID: 29120224 Ref: Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. PMID: 29122838 Ref: Implications of the tumor immune microenvironment for staging and therapeutics. PMID: 29192647 Ref: MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model. PMID: 29193199 Ref: Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. PMID: 29208565 Ref: Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. PMID: 29223828 Ref: Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. PMID: 29296022 Ref: High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer. PMID: 29308317 Ref: Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer. PMID: 29327160 Ref: Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer. PMID: 29328976 Ref: Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer. PMID: 29408916 Ref: Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. PMID: 29437869 Ref: TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. PMID: 29443964 Ref: Results and challenges of immune checkpoint inhibitors in colorectal cancer. PMID: 29471676 Ref: Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. PMID: 29471699 Ref: PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. PMID: 29492219 Ref: CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. PMID: 29520442 Ref: Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. PMID: 29542354 Ref: Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand in vitro. PMID: 29552177 Ref: Racial Disparities in the Molecular Landscape of Cancer. PMID: 29599344 Ref: Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression. PMID: 29632716 Ref: Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative Operation. PMID: 29662888 Ref: Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis. PMID: 29663398 Ref: Immunotherapy of Colon Cancer. PMID: 29705788 Ref: Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. PMID: 29710228 Ref: M7824, a novel bifunctional anti-PD-L1/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. PMID: 29721396 Ref: Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab: A case report. PMID: 29742733 Ref: Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer. PMID: 29770915 Ref: Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer. PMID: 29848685 Ref: PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins. PMID: 29854854 Ref: Impact of 5-Fu/oxaliplatin on mouse dendritic cells and synergetic effect with a colon cancer vaccine. PMID: 29861605 Ref: Targeting the TGFbeta pathway with galunisertib, a TGFbetaRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. PMID: 29866156 Ref: RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. PMID: 29872559 Ref: PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. PMID: 29872568 Ref: Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer. PMID: 29872576 Ref: Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. PMID: 29884866 Ref: TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. PMID: 29900052 Ref: Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer. PMID: 29900067 Ref: Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. PMID: 29915296 Ref: Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis. PMID: 29949671 Ref: CCL5-deficiency enhances intratumoral infiltration of CD8(+) T cells in colorectal cancer. PMID: 29991744 Ref: Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL/GPNMB antibody restores the in vitro integrity of T-cells from cancer patients. PMID: 30049749 Ref: (-)-4-O-(4-O-beta-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer. PMID: 30062658 Ref: Upregulation of PDL1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300mediated NFkappaB signaling. PMID: 30066852 Ref: DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. PMID: 30081950 Ref: Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model. PMID: 30087314 Ref: Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. PMID: 30128738 Ref: ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells. PMID: 30143021 Ref: Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. PMID: 30151257 Ref: Immunosuppression by Intestinal Stromal Cells. PMID: 30155625 Ref: EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer. PMID: 30156250 Ref: [Selection of Chemotherapy Regimen on the Basis of Monitoring NLR and Soluble PD-L1 during CRC Chemotherapy]. PMID: 30158411 Ref: The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers. PMID: 30161295 Ref: Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. PMID: 30166615 Ref: Immune environment in serrated lesions of the Colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. PMID: 30172913 Ref: Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. PMID: 30196908 Ref: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. PMID: 30202242 Ref: Follicular helper T cells promote the effector functions of CD8(+) T cells via the provision of IL-21, which is downregulated due to PD-1/PD-L1-mediated suppression in colorectal cancer. PMID: 30205088 Ref: Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. PMID: 30206410 Ref: Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors. PMID: 30221041 Ref: Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. PMID: 30221062 Ref: Stromal cell PD-L1 inhibits CD8+ T-cell antitumor immune responses and promotes colon cancer. PMID: 30228206 Ref: Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer. PMID: 30250590 Ref: Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. PMID: 30271205 Ref: Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation. PMID: 30272332 Ref: Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy. PMID: 30282671 Ref: PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells? PMID: 30285662 Ref: The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. PMID: 30288357 Ref: Association of IL-36gamma with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. PMID: 30315348 Ref: Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade. PMID: 30315349 Ref: Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer. PMID: 30353144 Ref: A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1 : Validation in Mouse Models and Human Cancer Tissues. PMID: 30373750 |